Lion Point Capital, LP
13F Reported Value
ⓘ$16.7M
Holdings
35
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Lion Point Capital, LP disclosed 35 positions worth $16.7M in its Form 13F-HR for Q1 2026, led by $PRAX (Praxis Precision Medicines, Inc.) at 8.6% of the equity portfolio, followed by $MLTX and $RPRX. During the quarter the fund opened 0 new positions and exited 4 and a full exit from $DAWN. The portfolio is most concentrated in Healthcare (98.8% of disclosed assets). All figures are sourced directly from Lion Point Capital, LP’s Form 13F-HR filing with the SEC under CIK 1643354.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- $1.4M4,450 sh
- —
Quality
$1.3M67,500 sh - —
Quality
$1.0M21,400 sh - —
Quality
$975.8K820,000 sh - —
Quality
$861.2K578,000 sh - 30.0
Quality
$841.0K36,000 sh - 35.3
Quality
$770.6K128,650 sh - 33.9
Quality
$691.5K112,434 sh - —
Quality
$660.3K62,000 sh - 41.6
Quality
$620.2K28,500 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $1.4M | 4,450 |
 MoonLake Immunotherapeutics$MLTX | — | $1.3M | 67,500 |
 Royalty Pharma plc$RPRX | — | $1.0M | 21,400 |
 Milestone Pharmaceuticals Inc.$MIST | — | $975.8K | 820,000 |
 GERON CORP$GERN | — | $861.2K | 578,000 |
 Syndax Pharmaceuticals Inc$SNDX | 30.0 | $841.0K | 36,000 |
 ARDELYX, INC.$ARDX | 35.3 | $770.6K | 128,650 |
 FENNEC PHARMACEUTICALS INC.$FENC | 33.9 | $691.5K | 112,434 |
 Benitec Biopharma Inc.$BNTC | — | $660.3K | 62,000 |
 Sarepta Therapeutics, Inc.$SRPT | 41.6 | $620.2K | 28,500 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Lion Point Capital, LP's 35 positions.
Showing top 10 of 35 holdings.
Sector Allocation
Healthcare
$16.5M
Industrials
$204,961
Full Holdings — Lion Point Capital, LP (Q1 2026)
All 35 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $1.4M | 8.6% | +0% | — |
| 2 | $MLTX | MoonLake Immunotherapeutics | $1.3M | 7.5% | +0% | — |
| 3 | $RPRX | Royalty Pharma plc | $1.0M | 6.1% | +0% | — |
| 4 | $MIST | Milestone Pharmaceuticals Inc. | $975,800 | 5.8% | +9% | — |
| 5 | $GERN | GERON CORP | $861,220 | 5.2% | +0% | — |
| 6 | $SNDX | Syndax Pharmaceuticals Inc | $840,960 | 5.0% | +0% | 30 |
| 7 | $ARDX | ARDELYX, INC. | $770,614 | 4.6% | +0% | 35.3 |
| 8 | $FENC | FENNEC PHARMACEUTICALS INC. | $691,469 | 4.1% | +0% | 33.9 |
| 9 | $BNTC | Benitec Biopharma Inc. | $660,300 | 4.0% | +0% | — |
| 10 | $SRPT | Sarepta Therapeutics, Inc. | $620,160 | 3.7% | +0% | 41.6 |
| 11 |  $IRON | Disc Medicine, Inc. | $517,914 | 3.1% | +0% | — |
| 12 |  $CUE | Cue Biopharma, Inc. | $506,436 | 3.0% | +0% | 23.2 |
| 13 |  $CMPS | COMPASS Pathways plc | $442,400 | 2.6% | +38% | — |
| 14 |  $BHVN | Biohaven Ltd. | $437,382 | 2.6% | +0% | — |
| 15 |  $LNTH | Lantheus Holdings, Inc. | $417,175 | 2.5% | +0% | 66.9 |
| 16 |  $JSPR | Jasper Therapeutics, Inc. | $407,433 | 2.4% | +0% | — |
| 17 |  $HUMA | Humacyte, Inc. | $394,355 | 2.4% | +30% | 5 |
| 18 |  $VTRS | Viatris Inc | $374,227 | 2.2% | +0% | 47.1 |
| 19 |  $KURA | Kura Oncology, Inc. | $373,980 | 2.2% | +0% | 9.1 |
| 20 |  $BBIO | BridgeBio Pharma, Inc. | $371,300 | 2.2% | +0% | 31.7 |
| 21 |  $DYN | Dyne Therapeutics, Inc. | $326,340 | 1.9% | +0% | — |
| 22 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $307,880 | 1.8% | +0% | — |
| 23 |  $PCRX | Pacira BioSciences, Inc. | $305,100 | 1.8% | +0% | 48 |
| 24 |  $EWTX | Edgewise Therapeutics, Inc. | $286,650 | 1.7% | +0% | — |
| 25 |  $MLYS | Mineralys Therapeutics, Inc. | $284,445 | 1.7% | +0% | — |
| 26 |  $MCRB | Seres Therapeutics, Inc. | $280,026 | 1.7% | +0% | 29.3 |
| 27 |  $JANX | Janux Therapeutics, Inc. | $264,100 | 1.6% | +0% | 24.8 |
| 28 |  $QURE | uniQure N.V. | $240,345 | 1.4% | +0% | — |
| 29 |  $RGNX | REGENXBIO Inc. | $222,908 | 1.3% | +0% | 26.9 |
| 30 |  $AZTA | Azenta, Inc. | $204,961 | 1.2% | +0% | 29.8 |
| 31 |  $INVA | Innoviva, Inc. | $191,060 | 1.1% | +0% | 75.2 |
| 32 |  $GHRS | GH Research PLC | $143,412 | 0.9% | +0% | — |
| 33 |  $ARQT | Arcutis Biotherapeutics, Inc. | $123,690 | 0.7% | +0% | 41.2 |
| 34 |  $IPHA | Innate Pharma SA | $103,873 | 0.6% | +0% | — |
| 35 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $65,350 | 0.4% | +0% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Lion Point Capital, LP including:
Track Lion Point Capital, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Lion Point Capital, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Lion Point Capital, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Lion Point Capital, LP (SEC CIK: 1643354), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Lion Point Capital, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.